Tenax Therapeutics, Inc. Common Stock (TENX) Stock
Fundamentals
Latest news
About Tenax Therapeutics, Inc. Common Stock
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher T. Giordano | CEO, President & Director | 1975 |
| Mr. Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer | 1973 |
| Dr. Stuart Rich M.D. | Chief Medical Officer & Director | 1950 |
| Mr. Thomas R. Staab II, CPA | Chief Financial Officer | 1968 |
| Mr. Doug Randall | Chief Business Officer | — |
| Dr. Douglas Hay Ph.D. | Executive Vice President of Regulatory Affairs | — |
| Mr. Timothy G. Healey M.B.A. | Chief Commercial Officer | 1966 |
| Dr. So-Young Kim M.D. | Executive Vice President of Clinical Development & Strategy | — |



